Evaluation of a neurodevelopmental model of schizophrenia-Early postnatal PCP treatment in attentional set-shifting

Behavioural Brain Research

Volumn 190, Issue 1, 2008, Pages 160-163

  Broberg, Brian Villumsen ^a,b   Dias, Rebecca ^a   Glenthøj, Birte Yding ^b,c   Olsen, Christina Kurre ^a  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Mental Health Services CPH   (Denmark)

Author keywords

Attentional set shifting; Cognition; Postnatal PCP; Rat; Schizophrenia

Indexed keywords

PHENCYCLIDINE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; COGNITIVE DEFECT; FEMALE; MALE; NEWBORN; NONHUMAN; OLFACTORY DISCRIMINATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RAT STRAIN; SCHIZOPHRENIA;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; ATTENTION; BEHAVIOR, ANIMAL; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EVALUATION STUDIES AS TOPIC; FEMALE; MALE; ODORS; PHENCYCLIDINE; PREGNANCY; RATS; SCHIZOPHRENIA; SEX FACTORS;

EID: 41949093235     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.02.020     Document Type: Article

References (35)

1. Andersen J.D., and Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of d-serine. Neuropsychopharmacology 29 (2004) 1080-1090
2. Barense M.D., Fox M.T., and Baxter M.G. Aged rats are impaired on an attentional set-shifting task sensitive to medial frontal cortex damage in young rats. Learn Mem 9 (2002) 191-201
3. Bayer S.A., Altman J., Russo R.J., and Zhang X. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14 (1993) 83-144
4. Benes F.M., and Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25 (2001) 1-27
5. Birrell J.M., and Brown V.J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20 (2000) 4320-4324
6. Chen K.C., Baxter M.G., and Rodefer J.S. Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting. Eur J Neurosci 20 (2004) 1081-1088
7. Clancy B., Darlington R.B., and Finlay B.L. Translating developmental time across mammalian species. Neuroscience 105 (2001) 7-17
8. Cochran S.M., Kennedy M., McKerchar C.E., Steward L.J., Pratt J.A., and Morris B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28 (2003) 265-275
9. Deutsch S.I., Mastropaolo J., and Rosse R.B. Neurodevelopmental consequences of early exposure to phencyclidine and related drugs. Clin Neuropharmacol 21 (1998) 320-332
10. Dias R., Robbins T.W., and Roberts A.C. Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380 (1996) 69-72
11. Fagerlund B., Mackeprang T., Gade A., and Glenthoj B.Y. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr 9 (2004) 364-374
12. Featherstone R.E., Rizos Z., Nobrega J.N., Kapur S., and Fletcher P.J. Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology 32 (2007) 483-492
13. Fenton W.S., Stover E.L., and Insel T.R. Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective. Psychopharmacology (Berl) 169 (2003) 365-366
14. Goetghebeur P.J.D., Bruun T., Spang Pedersen C., Nørgaard Johansson C., and Dias R. Evaluation of typical vs. atypical antipsychotics vs. modafinil to reverse the subchronic phencyclidine-induced attentional set-shifting impairment in rats. J Psychopharmacol 21 7(Suppl.) (2007) A24-A124 [abstract]
15. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 153 (1996) 321-330
16. Green M.F., Bracha H.S., Satz P., and Christenson C.D. Preliminary evidence for an association between minor physical anomalies and second trimester neurodevelopment in schizophrenia. Psychiatry Res 53 (1994) 119-127
17. Hyman S.E., and Fenton W.S. Medicine. What are the right targets for psychopharmacology?. Science 299 (2003) 350-351
18. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283 (1999) 70-74
19. Jentsch J.D., Tran A., Le D., Youngren K.D., and Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17 (1997) 92-99
20. Johnson K.M., Phillips M., Wang C., and Kevetter G.A. Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex. J Neurosci Res 52 (1998) 709-722
21. Johnston M.V., Haddad R., Carman-Young A., and Coyle J.T. Neurotransmitter chemistry of lissencephalic cortex induced in ferrets by fetal treatment with methylazoxymethanol acetate. Brain Res 256 (1982) 285-291
22. Lavin A., Moore H.M., and Grace A.A. Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats. Neuropsychopharmacology 30 (2005) 1426-1435
23. Lipska B.K., and Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23 (2000) 223-239
24. Matsui M., Sumiyoshi T., Arai H., Higuchi Y., and Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2007)
25. McLean S.L., Shemar G.K., Idris N.F., Mashall K.M., and Neill J.C. Deficits in attentional set-shifting in rats following sub-chronic phencyclidine (PCP) administration, effect of gender. Eur Coll Neuropsychopharmacol 17 4 (2007) S275 [abstract]
26. Owen A.M., Roberts A.C., Polkey C.E., Sahakian B.J., and Robbins T.W. Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 29 (1991) 993-1006
27. Pantelis C., Barber F.Z., Barnes T.R., Nelson H.E., Owen A.M., and Robbins T.W. Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37 (1999) 251-270
28. Reynolds G.P., Bdul-Monim Z., Neill J.C., and Zhang Z.J. Calcium binding protein markers of GABA deficits in schizophrenia-postmortem studies and animal models. Neurotox Res 6 (2004) 57-61
29. Rodefer J.S., Murphy E.R., and Baxter M.G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21 (2005) 1070-1076
30. Rodefer J.S., Nguyen T.N., Karlsson J.J., and Arnt J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT(6) receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology (2007)
31. Siuciak J.A., Chapin D.S., Harms J.F., Lebel L.A., McCarthy S.A., Chambers L., et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51 (2006) 386-396
32. Thaker G.K. Schizophrenia endophenotypes as treatment targets. Expert Opin Ther Targets 11 (2007) 1189-1206
33. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., and Sahakian B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29 (2004) 1363-1373
34. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J.L., and Johnson K.M. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107 (2001) 535-550
35. Wang C.Z., and Johnson K.M. Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J Neurosci Res 81 (2005) 284-292